Literature DB >> 10578147

Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.

P Wohlfart1, T Malinski, H Ruetten, U Schindler, W Linz, K Schoenafinger, H Strobel, G Wiemer.   

Abstract

1 In this study we examined the endothelium-dependent effect of YC-1 - a benzyl indazole derivative which directly activates soluble guanylyl cyclase (sGC) - on vascular relaxation and nitric oxide (NO) and guanosine-3',5'-cyclic monophosphate (cyclic GMP) in endothelial cells. 2 In preconstricted rat aortic rings with intact endothelium, YC-1 produced a concentration-dependent relaxation. However, the concentration response curve was shifted rightward to higher concentrations of YC-1, when (i) the aortas were pre-treated with L-NG-nitroarginine methylester (L-NAME) or (ii) the endothelium was removed. 3 Incubation of bovine aortic endothelial cells (BAEC) with YC-1 produced a concentration-dependent NO synthesis and release as assessed using a porphyrinic microsensor. Pre-incubating cells with L-NAME or with 8-bromo-cyclic GMP decreased this effect indicating that the YC-1 stimulation of NO synthesis is due to an activation of nitric oxide synthase, but not to an elevation of cyclic GMP. No direct effect of YC-1 on recombinant endothelial constitutive NO synthase activity was observed. 4 The YC-1 stimulated NO release was reduced by 90%, when extracellular free calcium was diminished. 5 In human umbilical vein endothelial cells (HUVEC), YC-1 stimulated intracellular cyclic GMP production in a concentration- and time-dependent manner. Stimulation of cyclic GMP was greater with a maximum concentration of YC-1 compared to calcium ionophore A23187. Similar effects were observed in BAEC and rat microvascular coronary endothelial cells (RMCEC). 6 When HUVEC and RMCEC were pre-treated with L-NG-nitroarginine (L-NOARG), the maximum YC-1 stimulated cyclic GMP increase was reduced by >/=50%. 7 These results indicate, that beside being a direct activator of sGC, YC-1 stimulates a NO-synthesis and release in endothelial cells which is independent of elevation of cyclic GMP but strictly dependent on extracellular calcium. The underlying mechanism needs to be determined further.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10578147      PMCID: PMC1571759          DOI: 10.1038/sj.bjp.0702921

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  YC-1, a novel activator of platelet guanylate cyclase.

Authors:  F N Ko; C C Wu; S C Kuo; F Y Lee; C M Teng
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

2.  Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme.

Authors:  A Friebe; G Schultz; D Koesling
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

3.  Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide.

Authors:  M Hoenicka; E M Becker; H Apeler; T Sirichoke; H Schröder; R Gerzer; J P Stasch
Journal:  J Mol Med (Berl)       Date:  1999-01       Impact factor: 4.599

4.  Colocalization of the genes coding for the alpha 3 and beta 3 subunits of soluble guanylyl cyclase to human chromosome 4 at q31.3-q33.

Authors:  G Giuili; N Roechel; U Scholl; M G Mattei; G Guellaen
Journal:  Hum Genet       Date:  1993-04       Impact factor: 4.132

5.  Different B1 kinin receptor expression and pharmacology in endothelial cells of different origins and species.

Authors:  P Wohlfart; J Dedio; K Wirth; B A Schölkens; G Wiemer
Journal:  J Pharmacol Exp Ther       Date:  1997-02       Impact factor: 4.030

6.  YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.

Authors:  C C Wu; F N Ko; S C Kuo; F Y Lee; C M Teng
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

7.  Characterization of the responses of isolated rings of rabbit left carotid artery. A potential protocol for the assessment of pathologically induced functional changes.

Authors:  P W Hadoke; R M Wadsworth; C L Wainwright
Journal:  J Pharmacol Toxicol Methods       Date:  1993-08       Impact factor: 1.950

8.  [Studies on heterocyclic compounds. XXXIV. Synthesis of furo[3,2-c]pyrazole derivatives. (2). Electrophilic substitution of 1,3-diphenylfuro[3,2-c]pyrazole (author's transl)].

Authors:  S Yoshina; A Tanaka; S C Kuo
Journal:  Yakugaku Zasshi       Date:  1978-02       Impact factor: 0.302

9.  Inhibition by sulfhydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor.

Authors:  L Jia; R F Furchgott
Journal:  J Pharmacol Exp Ther       Date:  1993-10       Impact factor: 4.030

10.  Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor.

Authors:  T Malinski; Z Taha
Journal:  Nature       Date:  1992-08-20       Impact factor: 49.962

View more
  15 in total

1.  The Rho-kinase inhibitor Y-27632 and the soluble guanylyl cyclase activator BAY41-2272 relax rabbit vaginal wall and clitoral corpus cavernosum.

Authors:  Selim Cellek
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

2.  Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells.

Authors:  Junhua Zhang; Zhonglin Xie; Yunzhou Dong; Shuangxi Wang; Chao Liu; Ming-Hui Zou
Journal:  J Biol Chem       Date:  2008-08-07       Impact factor: 5.157

3.  Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies.

Authors:  Johannes-Peter Stasch; Cristina Alonso-Alija; Heiner Apeler; Klaus Dembowsky; Achim Feurer; Torsten Minuth; Elisabeth Perzborn; Matthias Schramm; Alexander Straub
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

4.  Reduction of ICAM-1 expression by carbon monoxide via soluble guanylate cyclase activation accounts for modulation of neutrophil migration.

Authors:  Daniela Dal-Secco; Andressa Freitas; Monica A Abreu; Thiago P Garlet; Marcos A Rossi; Sérgio H Ferreira; João S Silva; José C Alves-Filho; Fernando Q Cunha
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-27       Impact factor: 3.000

5.  YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway.

Authors:  Chin-Chuan Hung; Horng-Huei Liou
Journal:  Invest New Drugs       Date:  2010-07-31       Impact factor: 3.850

6.  Amino Acids in Cell Signaling: Regulation and Function.

Authors:  Sudikshya Paudel; Guoyao Wu; Xiaoqiu Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cells.

Authors:  Lavoisier S Ramos-Espiritu; Kenneth C Hess; Jochen Buck; Lonny R Levin
Journal:  J Pharmacol Exp Ther       Date:  2011-06-10       Impact factor: 4.030

8.  A xanthine-based KMUP-1 with cyclic GMP enhancing and K(+) channels opening activities in rat aortic smooth muscle.

Authors:  B N Wu; R J Lin; C Y Lin; K P Shen; L C Chiang; I J Chen
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

9.  YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells.

Authors:  Xiao-Ming Liu; Kelly J Peyton; Natalia N Mendelev; Hong Wang; David A Tulis; William Durante
Journal:  Mol Pharmacol       Date:  2008-10-15       Impact factor: 4.436

Review 10.  Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.

Authors:  A Aversa; M Pili; A Fabbri; E Spera; G Spera
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.